Synthetic DNA of Unlimited Length
Need long DNA?
Next level DNA synthesis
Ribbon Biolabs revolutionary technology for the fast and efficient automated synthesis of DNA is here to enable the new wave of biotechnological innovation.
Through our unique technology combining biochemistry, computing and automation, Ribbon Biolabs will make complex DNA accessible and affordable for our customers in the biotech industry and in academia.
Ribbon Biolabs wants to place itself as the key player in synthetic DNA of any complexity, empowering its customers to tackle challenges and develop products that today are only possible in our imagination.
A breakthrough in DNA synthesis
By synthesising DNA molecules longer than 10.000 basepairs, Ribbon Biolabs hits a major milestone that goes beyond the present technological capabilities for the de novo synthesis fo DNA and redefines the current industry standards.
These achievements prove the capability and the potential of Ribbon Biolabs’ in-house synthesis platform InfiniSynth, a technology involving machine-learning and robotic automation for the enzymatic assembly of long DNA molecules.
Accelerate your R&D
We make synthetic DNA of any length available for your innovative application in biotechnology, biopharma or academic research. Whether you need long DNA molecules or variant libraries – with our radically novel technology, you will have it at hand in only days and at affordable cost.
Invest in the future of biotech
Synthetic biology is not only one of the most rapidly growing markets, it also has disruptive potential. The major bottleneck for its advance is the availability of synthetic DNA. Ribbon Biolabs’ cost-efficient platform for automated high-throughput production of long and complex DNA molecules will help to overcome this impediment.
Invest in the future of biotech
Synthetic biology is one of the most rapidly growing markets and has disruptive potential for many industries. The major bottleneck for its advance is the availability of synthetic DNA. Ribbon Biolabs’ platform for automated high-throughput production of long DNA will help to overcome this impediment.
Join our team
As an early-stage startup company with ambitious growth plans we are always looking for talented people to expand our diverse and interdisciplinary team. Besides a workplace in one of the most liveable cities of the world and a new state-of-the art laboratory we offer the opportunity to grow with the company.
News and Events
Meet us at SynBioBeta 2023
May 17, 2023 - VIENNA, AUSTRIA: SynBioBeta - the largest synthetic biology industry conference - is back in 2023 and Ribbon Biolabs is very excited to be part of it. For the first time, Ribbon Biolabs will be present with a company booth and offer a Lightning Talk on...
Ribbon Biolabs Appoints Jodi Barrientos as Chief Business Officer
May 10, 2023 - VIENNA, AUSTRIA: Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Jodi Barrientos as Chief Business Officer. With over 17 years of experience in industry-leading life science and diagnostics companies, Jodi Barrientos brings...
Ribbon Biolabs Reaches Key Milestone with Automation of InfiniSynth™ Platform for Commercial-scale, Unlimited Length DNA Synthesis
December 20, 2022 - VIENNA, AUSTRIA: Ribbon Biolabs, the DNA synthesis company, today announced the successful implementation of their innovative InfiniSynth™ platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone...
Article about Ribbon Biolabs in Trending Topics
The Austrian Innovation and Start-up-Portal reports about Ribbon Biolabs’ recent investment round …
Twitter Feed
;
So proud to be there @SynBioBeta2023 with our first company conference booth!! Stop by to meet our team and learn about our Early Access Program and how our long #DNAsynthesis can take your applications to the next level.
@hpvladar, @marcbrehme @JodiBarrientos
Less than a week to go! We can’t wait to see you at #SynBioBeta2023! Stop by booth 19 to to learn about our Early Access Program and how our long DNA synthesis can take your applications to the next level.
#SynBioBeta2023 #synbio #SyntheticDNA #biotechnology
Find more here: https://ribbonbiolabs.com/ribbon-biolabs-appoints-jodi-barrientos-as-cbo/
Ribbon Biolabs Appoints Jodi Barrientos as Chief Business Officer - Ribbon Biolabs
Ribbon Biolabs, the DNA synthesis company, today announced the successful implementation of their innovative InfiniSynth ...
ribbonbiolabs.com
We are excited to announce the appointment of Jodi Barrientos as the new Chief Business Officer of Ribbon Biolabs. Jodi’s expertise will be instrumental in achieving our goal of bringing to market our transformative #DNASynthesis technology.
#Welcome #Growth
Our co-founder Wladimir Labeikovsky is at #REpharmaUSA in Philadelphia eager to discuss how synthetic biology will enable biopharma innovations and sustainable healthcare. Feel free to contact him if you are at the event.
Our CEO Harold P. de Vladar Vladar is at the Synthetic Biology for Future Health conference at the Wellcome Genome Campus, Cambridge. In the “Translating tools to therapies” panel he will address new developments in Synth Bio.
@ribbonbiolabs #SynBioFH23 @wellcomegenome @hpvladar
Stay up-to-date on the state of the art in #DNAsynthesis with this great paper! #RibbonBiolabs cutting-edge technology is featured as a driving force behind the #syntheticbiology revolution.
DNA synthesis technologies to close the gene writing gap
Nature Reviews Chemistry - There is increasing demand for synthetic DNA. However, our ability to make, or write, D...
www.nature.com
Our Co-founder Wladimir Labeikovsky (@nucholab) had an exciting time attending the #SyntheticBiology-Based Therapeutics Summit last week in Boston. We are keen to see, how our #longDNA products can accelerate and enable the development of smart therapies.
